J Chin Med Assoc. 2021 Sep 20. doi: 10.1097/JCMA.0000000000000623. Online ahead of print.
ABSTRACT
BACKGROUND: Diabetes mellitus (DM) can worsen the prognosis or survival in prostate cancer (PC) patients. We investigated whether glycemic control impacts mortality in PC patients with existing diabetes.
METHODS: All PC patients with or without pre-existing DM were enrolled from 2006 to 2017. Mean haemoglobin A1c (HbA1c) values (<7%, 7-9%, ≥9%) were used to represent glycemic control. Major outcomes included all-cause, PC-specific, and non-PC mortalities. Statistical analyses were performed using Cox regression models with adjusted mean HbA1c and other related confounders.
RESULTS: A total of 831 PC patients were enrolled (non-DM group, n=690; DM group with a record of mean HbA1c values, n=141). Results showed that the DM group with mean HbA1c level ≥ 9% (n=14) had significantly increased risk for all-cause and non-PC mortality (HR:3.09, 95% CIs:1.15-8.32, p=0.025 and HR:5.49, 95% CIs:1.66-18.16, p=0.005, respectively), but not for PC-specific mortality (HR:1.03, 95% CIs:0.13-8.44, p=0.975), compared to the non-DM group.
CONCLUSION: Our findings indicate that PC patients with DM who had a mean HbA1c level ≥ 9% had higher risks of all-cause and non-PC mortality as compared with non-DM subjects. Further large and long-term studies are needed to verify the effect of glycemic control in PC patients with DM.
PMID:34561410 | DOI:10.1097/JCMA.0000000000000623
